Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Current Leases (2019 - 2025)

Keros Therapeutics' Current Leases history spans 7 years, with the latest figure at $2.4 million for Q4 2025.

  • For Q4 2025, Current Leases rose 21.74% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $2.4 million, up 21.74%, while the annual FY2025 figure was $2.4 million, 21.74% up from the prior year.
  • Current Leases reached $2.4 million in Q4 2025 per KROS's latest filing, up from $2.3 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.4 million in Q4 2025 to a low of $436000.0 in Q1 2021.
  • Average Current Leases over 5 years is $1.2 million, with a median of $944500.0 recorded in 2022.
  • Peak YoY movement for Current Leases: tumbled 47.22% in 2022, then skyrocketed 203.93% in 2024.
  • A 5-year view of Current Leases shows it stood at $862000.0 in 2021, then crashed by 47.22% to $455000.0 in 2022, then soared by 120.88% to $1.0 million in 2023, then surged by 96.82% to $2.0 million in 2024, then rose by 21.74% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Current Leases are $2.4 million (Q4 2025), $2.3 million (Q3 2025), and $2.2 million (Q2 2025).